804 related articles for article (PubMed ID: 15308613)
21. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
22. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.
Park BK; Kim CW; Kwon JE; Negi M; Koo YT; Lee SH; Baek DH; Noh YH; Kang SC
Pharm Biol; 2019 Dec; 57(1):90-98. PubMed ID: 30724641
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator.
Zhang X; Allan GF; Tannenbaum P; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Lundeen SG; Sui Z
J Steroid Biochem Mol Biol; 2013 Mar; 134():51-8. PubMed ID: 23098693
[TBL] [Abstract][Full Text] [Related]
24. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats.
Allan G; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Ng R; Sui Z; Lundeen S
J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):207-13. PubMed ID: 18502117
[TBL] [Abstract][Full Text] [Related]
25. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
26. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.
Gao W; Reiser PJ; Coss CC; Phelps MA; Kearbey JD; Miller DD; Dalton JT
Endocrinology; 2005 Nov; 146(11):4887-97. PubMed ID: 16099859
[TBL] [Abstract][Full Text] [Related]
27. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
28. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
29. Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Juniewicz PE; Barbolt TA; Egy MA; Frenette G; Dube JY; Tremblay RR
Prostate; 1990; 17(2):101-11. PubMed ID: 2169047
[TBL] [Abstract][Full Text] [Related]
30. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
Bauman TM; Sehgal PD; Johnson KA; Pier T; Bruskewitz RC; Ricke WA; Huang W
Prostate; 2014 Jun; 74(9):923-32. PubMed ID: 24789081
[TBL] [Abstract][Full Text] [Related]
31. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
Flores E; Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E
Steroids; 2003 Mar; 68(3):271-5. PubMed ID: 12628690
[TBL] [Abstract][Full Text] [Related]
32. Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats.
Jin BR; Chung KS; Kim HJ; An HJ
J Ethnopharmacol; 2019 May; 235():481-488. PubMed ID: 30708034
[TBL] [Abstract][Full Text] [Related]
33. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
34. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Imada S; Akaza H; Ami Y; Koiso K; Ideyama Y; Takenaka T
Eur Urol; 1997; 31(3):360-4. PubMed ID: 9129932
[TBL] [Abstract][Full Text] [Related]
35. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
36. A selective androgen receptor modulator for hormonal male contraception.
Chen J; Hwang DJ; Bohl CE; Miller DD; Dalton JT
J Pharmacol Exp Ther; 2005 Feb; 312(2):546-53. PubMed ID: 15347734
[TBL] [Abstract][Full Text] [Related]
37. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
38. Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status.
Buncharoen W; Saenphet K; Saenphet S; Thitaram C
J Ethnopharmacol; 2016 Dec; 194():483-494. PubMed ID: 27732901
[TBL] [Abstract][Full Text] [Related]
39. Effects of flutamide and finasteride on rat testicular descent.
Spencer JR; Torrado T; Sanchez RS; Vaughan ED; Imperato-McGinley J
Endocrinology; 1991 Aug; 129(2):741-8. PubMed ID: 1677329
[TBL] [Abstract][Full Text] [Related]
40. Sequential androgen blockade: a biological study in the inhibition of prostatic growth.
Fleshner NE; Trachtenberg J
J Urol; 1992 Dec; 148(6):1928-31. PubMed ID: 1331549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
